Hummingbird Bioscience takes in $125m Series C

Hummingbird Bioscience, a clinical-stage biotech company, has secured $125 million in Series C financing.

18 May 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles